采纳股份收盘上涨2.00%，滚动市盈率30.61倍，总市值23.67亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Canan Co., which closed at 19.36 yuan with a 2.00% increase, resulting in a rolling PE ratio of 30.61 times and a total market value of 2.367 billion yuan [1][2] - Canan Co. operates in the medical device industry, which has an average PE ratio of 46.44 times and a median of 30.39 times, placing Canan Co. at the 75th position in the industry ranking [1][2] - As of the Q3 2024 report, 26 institutions hold shares in Canan Co., with a total of 839,400 shares valued at 1.7 million yuan [1] Group 2 - Canan Co.'s main business involves the research, production, and sales of injection and puncture instruments and laboratory consumables, with its primary products being medical devices, animal instruments, and laboratory consumables [1] - The latest performance report for Q3 2024 shows that Canan Co. achieved an operating income of 292 million yuan, a year-on-year decrease of 0.50%, and a net profit of 57.452 million yuan, down 38.02% year-on-year, with a sales gross margin of 39.28% [1]